CSE’s Anil Mall chats with Chris Bunka, Chairman and CEO of Lexaria Bioscience Corp. (CSE:LXX) to discuss the company’s recently closed financing of US$11 million and the opportunities that capital has afforded the company’s ability to further prove out the effectiveness of its patented DehydraTECH™, drug delivery technology across multiple classes of bioactive substances or drugs.
Here’s an overview of what Anil and Chris cover in this edition of the #HashtagFinance podcast:
0:00 – Introducing Chris Bunka and Lexaria Bioscience
2:25 – Recent listing on NASDAQ and financing
4:40 – The team at Lexaria
7:30 – Chris’ background and what drives him
11:58 – DehydraTECH™ – drug enhancement delivery system
16:11 – Competing with Nanotechnology
18:50 – Utilizing patents with CBD
26:00 – Developing smoking alternatives w/ oral nicotine
33:00 – CBD from hemp
36:00 – Improved anti-viral drug delivery
40:15 – working with universities
44:20 – The best team he has ever worked with
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.
DehydraTECH has repeatedly demonstrated since 2016 with cannabinoids and nicotine the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is planned to be further evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oralbased nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide.
For more information, please visit www.lexariabioscience.com.
